Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/molecular-monitoring-TmcGjsOLuT
References (44)
-
M Emig, S Saussele, H Wittor (1999)
Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCRLeukemia, 13
-
N Thielen, B Holt, JJ Cornelissen (2013)
Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON)Eur J Cancer, 49
-
P Balasubramanian, E Chendamarai, P Markose (2012)
International reporting scale of BCR-ABL1 fusion transcript in chronic myeloid leukemia: first report from IndiaActa Haematol, 127
-
M Baccarani, G Saglio, J Goldman (2006)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetBlood, 108
-
M Baccarani, MW Deininger, G Rosti (2013)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Blood, 122
-
L Wang, K Pearson, JE Ferguson (2003)
The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemiaBr J Haematol, 120
-
MC Muller, N Gattermann, T Lahaye (2003)
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-CLeukemia, 17
-
L Foroni, G Wilson, G Gerrard (2011)
Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemiaBr J Haematol, 153
-
E Mensink, A Locht, A Schattenberg (1998)
Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCRBr J Haematol, 102
-
NC Cross, L Feng, J Bungey (1993)
Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reactionLeuk Lymphoma, 11
-
T Hughes, M Deininger, A Hochhaus (2006)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsBlood, 108
-
C Yoshida, L Fletcher, K Ohashi (2012)
Harmonization of molecular monitoring of chronic myeloid leukemia therapy in JapanInt J Clin Oncol, 17
-
D Verma, H Kantarjian, N Jain (2008)
Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alphaLeuk Lymphoma, 49
-
DM Ross, S Branford, JF Seymour (2013)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyBlood, 122
-
S Branford, NC Cross, A Hochhaus (2006)
Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemiaLeukemia, 20
-
S Merante, E Orlandi, P Bernasconi (2005)
Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuationHaematologica, 90
-
HE White, P Matejtschuk, P Rigsby (2010)
Establishment of the first world health organization international genetic reference panel for quantitation of BCR-ABL mRNABlood, 116
-
B Hanfstein, MC Muller, R Hehlmann (2012)
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)Leukemia, 26
-
M Baccarani, J Cortes, F Pane (2009)
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNetJ Clin Oncol, 27
-
H Kantarjian, M Talpaz, S O'Brien (2004)
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemiaBlood, 103
-
NC Cross, L Feng, A Chase (1993)
Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantationBlood, 82
-
DM Ross, S Branford, JF Seymour (2010)
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCRLeukemia, 24
-
S Guastafierro, U Falcone, M Celentano (2009)
Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literatureLeuk Res, 33
-
N Takahashi, T Kyo, Y Maeda (2012)
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemiaHaematologica, 97
-
J Cortes, M Talpaz, S O'Brien (2005)
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylateClin Cancer Res, 11
-
S Branford, L Fletcher, NC Cross (2008)
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trialsBlood, 112
-
M Sobrinho-Simoes, V Wilczek, J Score (2010)
In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinibBlood, 116
-
HM Kantarjian, JE Cortes, S O'Brien (2004)
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alphaBlood, 104
-
M Amabile, B Giannini, N Testoni (2001)
Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemiaHaematologica, 86
-
J Gabert, E Beillard, VH Velden (2003)
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer programLeukemia, 17
-
P Rousselot, F Huguet, D Rea (2007)
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 yearsBlood, 109
-
CA Heid, J Stevens, KJ Livak (1996)
Real time quantitative PCRGenome Res, 6
-
M Breccia, D Diverio, F Pane (2006)
Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferonLeuk Res, 30
-
NC Cross, HE White, MC Muller (2012)
Standardized definitions of molecular response in chronic myeloid leukemiaLeukemia, 26
-
E Beillard, N Pallisgaard, VH Velden (2003)
Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer programLeukemia, 17
-
TP Hughes, J Kaeda, S Branford (2003)
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemiaN Engl J Med, 349
-
NC Cross (2009)
Standardisation of molecular monitoring for chronic myeloid leukaemiaBest Pract Res Clin Haematol, 22
-
HE White, J Hedges, I Bendit (2013)
Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scaleClin Chem, 59
-
S Okabe, T Tauchi, Y Ishii (2007)
Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapyInt J Hematol, 85
-
S Branford, Z Rudzki, A Harper (2003)
Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phaseLeukemia, 17
-
MJ Mauro (2013)
Striving to achieve safe, permanent treatment discontinuation in chronic myeloid leukemiaLeuk Res, 37
-
MC Muller, NC Cross, P Erben (2009)
Harmonization of molecular monitoring of CML therapy in EuropeLeukemia, 23
-
FX Mahon, D Rea, J Guilhot (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trialLancet Oncol, 11
-
FX Mahon, G Etienne (2013)
Deep molecular response in chronic myeloid leukemia: the new goal of therapy?Clin Cancer Res
- Publisher
- Springer Journals
- Copyright
- Copyright © 2014 by Springer Science+Business Media New York
- Subject
- Medicine & Public Health; Hematology; Oncology; Geriatrics/Gerontology
- ISSN
- 1558-8211
- eISSN
- 1558-822X
- DOI
- 10.1007/s11899-013-0192-z
- pmid
- 24395452
- Publisher site
- See Article on Publisher Site
Abstract
More and more potent therapeutic approaches demand more and more sophisticated response monitoring. Soon after the introduction of the first tyrosine-kinase inhibitor (TKI) for chronic myeloid leukemia (CML) treatment, real time quantitative polymerase chain reaction (RQ-PCR) became the gold standard to follow the kinetics of reduction of disease burden and allow prognostic stratification. Continuous therapeutic improvement has led to increasingly ambitious treatment endpoints (now culminating in the possibility of achieving treatment free remission), which, in turn, has led to more and more refined measurement and definition of molecular response (MR) levels. Here, we will review the evolution of molecular response definitions and terminology, how specific MR levels currently provide key checkpoints in the context of optimal patient management, how molecular monitoring can best be performed nowadays and what future trends for further technological improvement can be.
Journal
Current Hematologic Malignancy Reports – Springer Journals
Published: Jan 7, 2014